Follow The Filings

BHVN Biohaven Ltd.

Health Care, filed as BIOHAVEN LTD (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 0.4%
  • $3.2M
  • 1 new 1 reduce

In 2026 Q2 James Silverman opened a position in Biohaven, while Nathan Fischel trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 0.39%
  2. James Silverman New 0.10%

Who owns BHVN

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.39%, was 1.6% Reduce −83.7% 137,593 $2M History
James Silverman, Opaleye Management 0.10% New 0.10% 77,915 $1.2M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BHVN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BHVN insider trades
  • $33.1M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. John W Childs Director
    Buy
    $864K 28,400 shares at $30.43 +1.2% to stake
    Traded Mar 4, 2025 Filed Mar 9
    ↗
  2. George C. Clark VP, Chief Accounting Officer
    Buy
    $145K 17,000 shares at $8.52 +567% to stake
    Traded Nov 17, 2025 Filed Nov 18, 2025
    ↗
  3. Gregory Bailey Director
    Buy
    $3M 400,000 shares at $7.50 +25% to stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
    ↗
  4. Vlad Coric CEO
    Buy
    $5M 666,666 shares at $7.50 +902% to stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
    ↗
  5. John W Childs Director
    Buy
    $25M 3,333,333 shares at $7.50 +144% to stake
    Traded Nov 13, 2025 Filed Nov 17, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 5 share withholdings for taxes, 5 option exercises, and 2 gifts.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$408.17M -$846.42M -$738.82M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $442.45M $538.47M $368.33M
Total non-current assets * $70.77M $76.64M $83.12M
Total assets $513.21M $615.11M $451.45M
Total current liabilities $55.42M $154.23M $115.93M
Total non-current liabilities * $29.81M $37.44M $283.44M
Total equity $427.98M $423.44M $52.07M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$331.72M -$582.45M -$609.44M
Cash from investing $129.83M -$244.97M $300.56M
Cash from financing $211.91M $677.77M $439.12M
Net change in cash $9.52M -$149.58M $130.24M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.